Granular cell tumors are uncommon, usually benign tumors of Schwann cell origin. The malignant variant is extremely rare, representing <2% of all granular cell tumors. Therefore, standard systemic chemotherapy for this disease does not exist. The present study reports the case of a 40-year-old female with a malignant granular cell tumor that originally arose in the right orbit and subsequently relapsed. The patient was started on pazopanib monotherapy following treatment with two investigational drugs, a smoothened inhibitor and then a phosphatidylinositol 3-kinase inhibitor, as part of a clinical trial. Although additional radiotherapy for local control was necessary, the lung metastases remained stable during the pazopanib monotherapy, which lasted for 7 months, following which a clinically stable disease state was determined. This case suggests that pazopanib can be a treatment option for the stabilization of disease progression in metastatic malignant granular cell tumor.
CITATION STYLE
Morita, S., Hiramatsu, M., Sugishita, M., Gyawali, B., Shibata, T., Shimokata, T., … Ando, Y. (2015). Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report. Oncology Letters, 10(2), 972–974. https://doi.org/10.3892/ol.2015.3263
Mendeley helps you to discover research relevant for your work.